Amylyx Pharmaceuticals (AMLX) Restructuring Costs (2024)
Amylyx Pharmaceuticals (AMLX) recorded quarterly Restructuring Costs of $22.9 million in Q2 2024.
Amylyx Pharmaceuticals (AMLX) Restructuring Costs (2024) Analysis & Trends
Amylyx Pharmaceuticals' Restructuring Costs history runs 1 years deep, the most recent figure standing at $22.9 million for Q2 2024.
- In Q2 2024, Restructuring Costs changed N/A year-over-year to $22.9 million; the TTM figure through Jun 2025 stood at $22.9 million (changed N/A YoY), while the FY2024 annual figure was $22.9 million, changed N/A from the prior year.
- Restructuring Costs was $22.9 million for Q2 2024 at Amylyx Pharmaceuticals.
- In the past five years, Restructuring Costs ranged from a high of $22.9 million in Q2 2024 to a low of $22.9 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Amylyx Pharmaceuticals | 1.44 Bn | 1.44 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 22.85 Mn |